Protagonist Therapeutics and Takeda shared positive 52-week results from the Phase 3 VERIFY study of rusfertide for polycythemia vera at ASH Annual Meeting. 61.9% of patients maintained absence of phlebotomy eligibility. No new safety concerns were noted. Patients crossing over from placebo to rusfertide showed similar outcomes to those initially on rusfertide. Combined REVIVE and THRIVE studies showed a 13-fold reduction in phlebotomies over four years with rusfertide. Rusfertide has the potential to address unmet needs in PV treatment by maintaining HCT levels below 45%.

Read more at Nasdaq: Protagonist And Takeda Report 52-Week Rusfertide Data In Polycythemia Vera